Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics

January 7, 2011 By Bio-Medicine.Org

SAN DIEGO, Jan. 7, 2011 /PRNewswire/ — ADVENTRX
Pharmaceuticals, Inc. (NYSE Amex:
ANX
) today announced that it has signed a term sheet to acquire
a private company that holds certain rights and know-how to
poloxamer-based therapeutics. The term sheet is non-binding on both
ADVENTRX and the target company.

About the Potential Transaction

Current discussions with the target company contemplate an
all-stock acquisition by merger. Other than an upfront issuance of
approximately 19% of ADVENTRX’s currently outstanding common stock
(of which only 6.5% would be fully-vested upon issuance and 12.5%
would vest subject to successfully attaining the initial
development milestone), the acquisition consideration would be
issued based on the target company’s lead product candidate, or the
TPC, successfully attaining development milestones, such as first
patient dosing in a pivotal trial, acceptance by the FDA of a New
Drug Application, or NDA, for the TPC and NDA approval.

Based on current discussions, of the total acquisition
consideration that could be paid, approximately 71% is tied to NDA
acceptance and NDA approval. If all development milestones are
achieved, including NDA approval, stockholders of the target
company would own approximately 47% of ADVENTRX (based on
ADVENTRX’s currently outstanding shares of common stock but
including the shares issued to the target company’s
stockholders).

If ADVENTRX’s stockholders do not approve the issuance of shares
beyond the upfront issuance as required by NYSE Amex listing
standards, ADVENTRX expects to pay the target company’s
stockholders in cash the value of the shares it otherwise would
have issued in excess of the 19% upfront issuance described above,
with the NDA acceptance and NDA approval milestone payments payable
based on net sales of the TPC and all milestone payments payable in
quarterly instal

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies
Biotronik
FDA approves Biotronik’s programmer for implanted cardiac rhythm management devices

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech